Rabusertib (LY2603618)

Rabusertib (LY2603618) is an inhibitor of CHK1 and CHK used in studies of DNA Damage Response and Apoptosis and related signaling programs. In practice, this places the compound in experiments that measure checkpoint activation, DNA repair, and genome-stability control and caspase-associated cell-death signaling and survival decisions in apoptosis, autophagy, and cancer models.

By inhibiting CHK1 and CHK, Rabusertib (LY2603618) can be used to examine checkpoint activation, DNA repair, and genome-stability control and caspase-associated cell-death signaling and survival decisions. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving CHK1 and CHK
• Pathway perturbation studies connected to DNA Damage Response and Apoptosis and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Rabusertib (LY2603618) is appropriate when a defined chemical perturbant is needed to connect CHK1 and CHK with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.